SI2242749T1 - Novi piridinoni in piridazinoni - Google Patents

Novi piridinoni in piridazinoni

Info

Publication number
SI2242749T1
SI2242749T1 SI200930630T SI200930630T SI2242749T1 SI 2242749 T1 SI2242749 T1 SI 2242749T1 SI 200930630 T SI200930630 T SI 200930630T SI 200930630 T SI200930630 T SI 200930630T SI 2242749 T1 SI2242749 T1 SI 2242749T1
Authority
SI
Slovenia
Prior art keywords
pyridazinones
pyridinones
novel
novel pyridinones
Prior art date
Application number
SI200930630T
Other languages
English (en)
Inventor
Nolan James Dewdney
Joshua Kennedy-Smith
Rama K. Kondru
Bradley E. Loe
Yan Lou
Joel Mcintosh
Timothy D. Owens
Michael Soth
Zachary Kevin Sweeney
Joshua Paul Gergely Taygerly
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of SI2242749T1 publication Critical patent/SI2242749T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200930630T 2008-02-05 2009-01-27 Novi piridinoni in piridazinoni SI2242749T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2620408P 2008-02-05 2008-02-05
US12251008P 2008-12-15 2008-12-15
EP09709135.9A EP2242749B1 (en) 2008-02-05 2009-01-27 Novel pyridinones and pyridazinones
PCT/EP2009/050875 WO2009098144A1 (en) 2008-02-05 2009-01-27 Novel pyridinones and pyridazinones

Publications (1)

Publication Number Publication Date
SI2242749T1 true SI2242749T1 (sl) 2013-07-31

Family

ID=40413736

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200930630T SI2242749T1 (sl) 2008-02-05 2009-01-27 Novi piridinoni in piridazinoni

Country Status (30)

Country Link
EP (1) EP2242749B1 (sl)
JP (1) JP5259739B2 (sl)
KR (1) KR101308803B1 (sl)
CN (1) CN101932573B (sl)
AR (1) AR070408A1 (sl)
AU (1) AU2009211514B2 (sl)
BR (1) BRPI0907915A2 (sl)
CA (1) CA2710462C (sl)
CL (1) CL2009000229A1 (sl)
CO (1) CO6290767A2 (sl)
CR (1) CR11598A (sl)
CY (1) CY1114114T1 (sl)
DK (1) DK2242749T3 (sl)
EC (1) ECSP10010384A (sl)
ES (1) ES2420846T3 (sl)
HK (1) HK1146826A1 (sl)
HR (1) HRP20130615T1 (sl)
IL (1) IL206357A (sl)
MA (1) MA32064B1 (sl)
MX (1) MX2010008197A (sl)
MY (1) MY158411A (sl)
NZ (1) NZ586916A (sl)
PE (1) PE20091484A1 (sl)
PL (1) PL2242749T3 (sl)
PT (1) PT2242749E (sl)
RU (1) RU2505538C2 (sl)
SI (1) SI2242749T1 (sl)
TW (1) TWI382024B (sl)
WO (1) WO2009098144A1 (sl)
ZA (1) ZA201005539B (sl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2297142B1 (en) 2008-06-24 2015-10-14 F. Hoffmann-La Roche AG Novel substituted pyridin-2-ones and pyridazin-3-ones
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CA2748414A1 (en) * 2009-04-24 2010-10-28 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
AR078320A1 (es) 2009-09-04 2011-11-02 Biogen Idec Inc Derivados nitrogenados heterociclicos inhibidores de tirosinquinasas de bruton(btk), formulaciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y canceres.
CA2798634C (en) * 2010-05-07 2019-04-16 Gilead Connecticut, Inc. Pyridone and aza-pyridone compounds and methods of use
EP2394998A1 (en) * 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
MX345170B (es) 2011-05-17 2017-01-19 Hoffmann La Roche Inhibidores de la tirosina-cinasa de bruton.
EP2744804B1 (en) 2011-08-17 2017-05-17 F. Hoffmann-La Roche AG Inhibitors of bruton's tyrosine kinase
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
AU2013243898A1 (en) 2012-04-05 2014-10-23 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013157022A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CA2881761A1 (en) * 2012-09-13 2014-03-20 Christine E. Brotherton-Pleiss Inhibitors of bruton's tyrosine kinase
RU2015120216A (ru) * 2012-11-16 2017-01-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
WO2014083026A1 (en) * 2012-11-30 2014-06-05 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
KR101737724B1 (ko) 2013-03-05 2017-05-29 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
US9663494B2 (en) 2013-03-05 2017-05-30 Hoffmann-La Roche Inc. Inhibitors of bruton's tyrosine kinase
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
ES2619125T3 (es) 2013-04-25 2017-06-23 Beigene, Ltd. Compuestos heterocíclicos fusionados como inhibidores de proteína cinasa
CN104177338B (zh) * 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
CN105358545A (zh) * 2013-07-03 2016-02-24 豪夫迈·罗氏有限公司 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物
HRP20221262T1 (hr) 2013-09-13 2022-12-09 Beigene Switzerland Gmbh Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava
KR101813830B1 (ko) * 2013-12-05 2017-12-29 에프. 호프만-라 로슈 아게 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물
WO2016000619A1 (en) 2014-07-03 2016-01-07 Beigene, Ltd. Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
JP6507234B2 (ja) * 2014-10-02 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼ（ｂｔｋ）によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物
WO2017123695A1 (en) * 2016-01-13 2017-07-20 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
ES2886080T3 (es) 2016-03-31 2021-12-16 Takeda Pharmaceuticals Co Complejos de isoquinolinil triazolona
AU2017293423B2 (en) 2016-07-05 2023-05-25 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
RU2019104758A (ru) 2016-07-21 2020-08-21 Байоджен Ма Инк. Сукцинатные формы и композиции ингибиторов тирозинкиназы брутона
CN116478166A (zh) 2016-08-16 2023-07-25 百济神州(苏州)生物科技有限公司 一种化合物的晶型、其制备和用途
EP3500299B1 (en) 2016-08-19 2023-12-13 BeiGene Switzerland GmbH Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
US20190201409A1 (en) 2016-09-19 2019-07-04 Mei Pharma, Inc. Combination therapy
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CN106967073A (zh) * 2017-04-24 2017-07-21 刘双伟 一种治疗类风湿性关节炎的药物
CN106946891B (zh) * 2017-05-08 2018-07-13 宿州市徽腾知识产权咨询有限公司 一种用于治疗类风湿性关节炎的药物
CN110799543A (zh) 2017-06-26 2020-02-14 百济神州有限公司 肝细胞癌的免疫治疗
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
EP3867242A1 (en) 2018-10-15 2021-08-25 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
JP2022526025A (ja) 2019-04-09 2022-05-20 ニューリックス セラピューティクス，インコーポレイテッド Ｃｂｌ－ｂ阻害のための３－置換ピペリジン化合物、並びに癌ワクチン及び／又は腫瘍溶解性ウイルスと組み合わせたＣｂｌ－ｂ阻害剤の使用
MX2021013751A (es) 2019-05-17 2022-01-26 Nurix Therapeutics Inc Compuestos de ciano ciclobutilo para la inhibicion del protooncogen b de linfoma de linaje b de casitas (cbl-b) y usos de los mismos.
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US20230024442A1 (en) * 2019-11-08 2023-01-26 Nurix Therapeutics, Inc. Bifunctional compounds for grading btk via ubiquitin proteosome pathway
AU2020397920A1 (en) 2019-12-04 2022-06-16 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3951395B2 (ja) * 1996-12-13 2007-08-01 田辺製薬株式会社 ピリジン誘導体、その製法及びその合成中間体
RU2242474C2 (ru) * 1999-03-12 2004-12-20 Бёрингер Ингельхайм Фармасьютиклз, Инк. Соединения, пригодные в качестве противовоспалительных агентов
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US8101770B2 (en) * 2004-12-16 2012-01-24 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
MY140868A (en) * 2004-12-24 2010-01-29 Astrazeneca Ab Amide derivatives
CA2601628C (en) * 2005-03-10 2014-05-13 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
WO2006124731A2 (en) * 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
ES2351939T3 (es) * 2005-08-09 2011-02-14 Irm Llc Compuestos y composiciones como inhibidores de proteínas cinasas.
CA2620269A1 (en) * 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
MX2008014618A (es) * 2006-05-15 2008-11-28 Irm Llc Composiciones y metodos para inhibidores de cinasas del receptor fgf.

Also Published As

Publication number Publication date
IL206357A (en) 2013-12-31
JP5259739B2 (ja) 2013-08-07
AU2009211514A1 (en) 2009-08-13
TW200938538A (en) 2009-09-16
PL2242749T3 (pl) 2013-09-30
RU2505538C2 (ru) 2014-01-27
CA2710462C (en) 2015-11-24
CA2710462A1 (en) 2009-08-13
CN101932573B (zh) 2014-06-11
AU2009211514B2 (en) 2014-02-20
ZA201005539B (en) 2011-04-28
KR101308803B1 (ko) 2013-09-13
CL2009000229A1 (es) 2010-06-04
AR070408A1 (es) 2010-04-07
WO2009098144A1 (en) 2009-08-13
HK1146826A1 (en) 2011-07-15
CO6290767A2 (es) 2011-06-20
EP2242749B1 (en) 2013-04-10
DK2242749T3 (da) 2013-06-17
CR11598A (es) 2010-10-27
CN101932573A (zh) 2010-12-29
MX2010008197A (es) 2010-08-23
PT2242749E (pt) 2013-07-16
NZ586916A (en) 2012-06-29
TWI382024B (zh) 2013-01-11
ECSP10010384A (es) 2010-09-30
IL206357A0 (en) 2010-12-30
CY1114114T1 (el) 2016-07-27
BRPI0907915A2 (pt) 2015-07-28
EP2242749A1 (en) 2010-10-27
RU2010136665A (ru) 2012-03-20
HRP20130615T1 (en) 2013-08-31
PE20091484A1 (es) 2009-10-03
MA32064B1 (fr) 2011-02-01
ES2420846T3 (es) 2013-08-27
MY158411A (en) 2016-10-14
KR20100093130A (ko) 2010-08-24
JP2011511027A (ja) 2011-04-07

Similar Documents

Publication Publication Date Title
HRP20130615T1 (en) Novel pyridinones and pyridazinones
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
HK1196358A1 (en) Substituted pyridin-2-ones and pyridazin-3-ones -2--3-
IL210804A (en) Benzylidenehydrazides and their uses
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
ZA201100372B (en) Wounddressing and headgear
GB0808575D0 (en) Compilign and linking
ZA201103456B (en) Leukolectins and uses thereof
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
GB0903299D0 (en) Composition and methods
EP2247601A4 (en) THIAZOPYRIMIDINONE AND APPLICATIONS THEREOF
GB0912744D0 (en) Methods and uses
AP3008A (en) Pupicidal and larvicidal composition
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
GB0813359D0 (en) Halfin and/or platerfin
GB0707069D0 (en) Methods and uses
HK1120988A2 (en) Nail-ness and quick-install house
GB0810609D0 (en) Methods and uses
GB0816523D0 (en) Methods and uses
GB0808857D0 (en) Methdos and uses
TWI366394B (en) Synchronnization devices and methods
GB0722451D0 (en) Methods and uses
GB0707609D0 (en) Methods and uses
TWI369138B (en) Speaker and application thereof
HUP0800405A2 (en) Environment-friendly biocidis and use thereof